Literature DB >> 22589371

Skin ceramide alterations in first-episode schizophrenia indicate abnormal sphingolipid metabolism.

Stefan Smesny1, Christian E H Schmelzer, Anke Hinder, Alexandra Köhler, Christiane Schneider, Maria Rudzok, Ulrike Schmidt, Berko Milleit, Christine Milleit, Igor Nenadic, Heinrich Sauer, Reinhard H H Neubert, Joachim W Fluhr.   

Abstract

There is considerable evidence for specific pathology of lipid metabolism in schizophrenia, affecting polyunsaturated fatty acids and in particular sphingolipids. These deficits are assumed to interfere with neuronal membrane functioning and the development and maintenance of myelin sheaths. Recent studies suggest that some of these lipid pathologies might also be detected in peripheral skin tests. In this study, we examined different skin lipids and their relation to schizophrenia. We assessed epidermal lipid profiles in 22 first-episode antipsychotic-naïve schizophrenia patients and 22 healthy controls matched for age and gender using a hexan/ethanol extraction technique and combined high-performance thin-layer chromatography/gas-chromatography. We found highly significant increase of ceramide AH and NH/AS classes in patients and decrease of EOS and NP ceramide classes. This is the first demonstration of specific peripheral sphingolipid alterations in schizophrenia. The results support recent models of systemic lipid pathology and in particular of specific sphingolipids, which are crucial in neuronal membrane integrity. Given recent findings showing amelioration of psychopathology using fatty acid supplementation, our findings also bear relevance for sphingolipids as potential biomarkers of the disease.

Entities:  

Keywords:  brain white matter; ceramides; epidermis; omega-3 fatty acids; schizophrenia; sphingolipids

Mesh:

Substances:

Year:  2012        PMID: 22589371      PMCID: PMC3686445          DOI: 10.1093/schbul/sbs058

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  41 in total

Review 1.  The role of phospholipases A2 in schizophrenia.

Authors:  M H Law; R G H Cotton; G E Berger
Journal:  Mol Psychiatry       Date:  2006-06       Impact factor: 15.992

Review 2.  Lipid raft microdomains and neurotransmitter signalling.

Authors:  John A Allen; Robyn A Halverson-Tamboli; Mark M Rasenick
Journal:  Nat Rev Neurosci       Date:  2006-12-29       Impact factor: 34.870

Review 3.  Bioactive lipids in schizophrenia.

Authors:  Gregor E Berger; Stefan Smesny; G Paul Amminger
Journal:  Int Rev Psychiatry       Date:  2006-04

Review 4.  Apoptotic mechanisms in the pathophysiology of schizophrenia.

Authors:  L Fredrik Jarskog; Leisa A Glantz; John H Gilmore; Jeffrey A Lieberman
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-06       Impact factor: 5.067

5.  Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene.

Authors:  Mirjana Tosic; Jurg Ott; Sandra Barral; Pierre Bovet; Patricia Deppen; Fulvia Gheorghita; Marie-Louise Matthey; Josef Parnas; Martin Preisig; Michael Saraga; Alessandra Solida; Sally Timm; August G Wang; Thomas Werge; Michel Cuénod; Kim Quang Do
Journal:  Am J Hum Genet       Date:  2006-07-31       Impact factor: 11.025

Review 6.  A review of diffusion tensor imaging studies in schizophrenia.

Authors:  Marek Kubicki; Robert McCarley; Carl-Fredrik Westin; Hae-Jeong Park; Stephan Maier; Ron Kikinis; Ferenc A Jolesz; Martha E Shenton
Journal:  J Psychiatr Res       Date:  2005-07-14       Impact factor: 4.791

7.  The role of oligodendrocyte pathology in schizophrenia.

Authors:  Natalya A Uranova; Victor M Vostrikov; Olga V Vikhreva; Ivetta S Zimina; Natalya S Kolomeets; Diana D Orlovskaya
Journal:  Int J Neuropsychopharmacol       Date:  2007-02-21       Impact factor: 5.176

Review 8.  Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability.

Authors:  C J Carter
Journal:  Schizophr Res       Date:  2006-07-13       Impact factor: 4.939

9.  Separation and mass spectrometric characterization of covalently bound skin ceramides using LC/APCI-MS and Nano-ESI-MS/MS.

Authors:  Hany Farwanah; Barbara Pierstorff; Christian E H Schmelzer; Klaus Raith; Reinhard H H Neubert; Thomas Kolter; Konrad Sandhoff
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-24       Impact factor: 3.205

10.  Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study.

Authors:  Thomas J Whitford; Stuart M Grieve; Tom F D Farrow; Lavier Gomes; John Brennan; Anthony W F Harris; Evian Gordon; Leanne M Williams
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

View more
  16 in total

1.  Harnessing the power of yeast to elucidate the role of sphingolipids in metabolic and signaling processes pertinent to psychiatric disorders.

Authors:  Shyamalagauri Jadhav; Miriam L Greenberg
Journal:  Clin Lipidol       Date:  2014-11-01

2.  Clozapine Modulates Glucosylceramide, Clears Aggregated Proteins, and Enhances ATG8/LC3 in Caenorhabditis elegans.

Authors:  Limin Hao; Oshrit Ben-David; Suzann M Babb; Anthony H Futerman; Bruce M Cohen; Edgar A Buttner
Journal:  Neuropsychopharmacology       Date:  2016-10-06       Impact factor: 7.853

3.  Impaired Membrane Lipid Homeostasis in Schizophrenia.

Authors:  Minghui Li; Yan Gao; Dandan Wang; Xiaowen Hu; Jie Jiang; Ying Qing; Xuhan Yang; Gaoping Cui; Pengkun Wang; Juan Zhang; Liya Sun; Chunling Wan
Journal:  Schizophr Bull       Date:  2022-09-01       Impact factor: 7.348

4.  Disrupted leptin-fatty acid biosynthesis is an early manifestation of metabolic abnormalities in schizophrenia.

Authors:  Mohammad M Khan
Journal:  World J Psychiatry       Date:  2022-06-19

5.  Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia.

Authors:  Shashwath A Meda; Gualberto Ruaño; Andreas Windemuth; Kasey O'Neil; Clifton Berwise; Sabra M Dunn; Leah E Boccaccio; Balaji Narayanan; Mohan Kocherla; Emma Sprooten; Matcheri S Keshavan; Carol A Tamminga; John A Sweeney; Brett A Clementz; Vince D Calhoun; Godfrey D Pearlson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

Review 6.  The promise of biological markers for treatment response in first-episode psychosis: a systematic review.

Authors:  Guillaume Fond; Marc-Antoine d'Albis; Stéphane Jamain; Ryad Tamouza; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Iris E Sommer; Inge Winter-van Rossum; Shitij Kapur; René S Kahn; Dan Rujescu; Marion Leboyer
Journal:  Schizophr Bull       Date:  2015-03-10       Impact factor: 9.306

7.  Genetic Sources of Subcomponents of Event-Related Potential in the Dimension of Psychosis Analyzed From the B-SNIP Study.

Authors:  Balaji Narayanan; Lauren E Ethridge; Kasey O'Neil; Sabra Dunn; Ian Mathew; Neeraj Tandon; Vince D Calhoun; Gualberto Ruaño; Mohan Kocherla; Andreas Windemuth; Brett A Clementz; Carol A Tamminga; John A Sweeney; Matcheri S Keshavan; Godfrey D Pearlson
Journal:  Am J Psychiatry       Date:  2015-01-23       Impact factor: 18.112

8.  Effects of Essential Oils and Polyunsaturated Fatty Acids on Canine Skin Equivalents: Skin Lipid Assessment and Morphological Evaluation.

Authors:  S Cerrato; L Ramió-Lluch; D Fondevila; D Rodes; P Brazis; A Puigdemont
Journal:  J Vet Med       Date:  2013-11-06

Review 9.  Methodological Considerations for Lipid and Polar Component Analyses in Human Skin Stratum Corneum.

Authors:  E Berdyshev; I Bronova; D Y M Leung; E Goleva
Journal:  Cell Biochem Biophys       Date:  2021-07-15       Impact factor: 2.989

10.  Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy.

Authors:  J C Naviaux; M A Schuchbauer; K Li; L Wang; V B Risbrough; S B Powell; R K Naviaux
Journal:  Transl Psychiatry       Date:  2014-06-17       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.